Asparkam-L, 45.2mg/ml+40 mg/ml 10 ml 10 pcs

Elimination of potassium and magnesium deficiency, normalization of electrolyte balance, improvement of myocardial metabolism. The mechanism of action of the drug is associated with the effective participation of L-asparaginate in the transport of magnesium and potassium ions into the intracellular space.

Magnesium activates sodium-potassium-ATPase, removing sodium ions from the cell and returning potassium ions; it reduces sodium content and prevents its exchange for calcium in vascular smooth muscle, reducing their resistance. Potassium stimulates the synthesis of adenosine triphosphate, glycogen, proteins, acetylcholine, etc.

The two ions maintain polarization/cell membranes. The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, and heart muscle function. Due to magnesium ions it participates in the processes of energy input and expenditure, normalizes membrane permeability, neuromuscular conduction, deoxyribonucleic acid and ribonucleic acid synthesis, cell growth, cell division, oxygen assimilation, and phosphate synthesis.

Indications

To eliminate potassium and magnesium deficiency as an adjunct in various manifestations of coronary heart disease, including acute myocardial infarction; chronic circulatory insufficiency; arrhythmias (arrhythmias caused by overdose of heart glycosides).

Active ingredient

Composition

Active substances:

Potassium L-asparaginate anhydrous – 45.20 g (10.33 g potassium),

magnesium L-asparaginate anhydrous – 40.00 g (3.37 g magnesium),

derived according to the following prescription:

L-aspartic acid – 74.00 g,

potassium hydroxide (potassium hydroxide) – 14.82 g,

Magnesium oxide – 5.59 g

Auxiliary substances:

Sorbitol (sorbitol) – 50.00 g,

water for injection – up to 1 liter.

How to take, the dosage

The drug is administered intravenously (by drip or stream).

The dose of the drug is determined individually depending on the indications for use. The drug is administered intravenously by drop-flow drops at a rate of 25 drops per 1 minute 1 to 2 times a day in 10-20 ml (1-2 ampoules in 10 ml or 2-4 ampoules in 5 ml) diluted in 100-200 ml of sodium chloride isotonic solution or 5% glucose solution.

In case of jet injection the contents of 1 ampoule of 10 ml or 2 ampoules of 5 ml are diluted in 20 ml of sterile water for injection or 5% glucose solution and injected slowly (not more than 5 ml per minute) into a vein.

Interaction

Potassium-saving diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs – risk of hyperkalemia up to the development of arrhythmia and asystole.

Manages hypokalemia caused by glucocorticosteroids.

Reduces unwanted effects of cardiac glycosides.

Due to the content of magnesium ions it reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

Anesthetics increase the suppressive effect of magnesium on the central nervous system.

May increase neuromuscular blockade caused by depolarizing myorelaxants (atracurium besylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide).

Calcitriol increases the concentration of magnesium in the blood plasma, calcium preparations reduce the effect of magnesium.

The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerability).

Special Instructions

There have been no studies to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Hypersensitivity to the drug, sorbitol, hyperkalemia, hypermagnesemia, acute and chronic renal failure, insufficiency of the adrenal cortex, atrioventricular block of II and III degree, cardiogenic shock, oliguria – anuria, acute metabolic acidosis, severe myasthenia gravis, dehydration, Addison’s disease, arterial hypotension, pregnancy, lactation, age under 18 years (effectiveness and safety not established).

Side effects

Nausea, dizziness, flushed face, thirst, decreased blood pressure, hyporeflexia are possible. The phenomena usually subside with reduction of the drug dose.
All symptoms of hyperkalemia and hypermagnesemia may appear with rapid intravenous administration.

Hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnesemia (facial hyperemia, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, seizures); when parenteral administration – atrioventricular blockade, paradoxical reaction (increased number of extrasystoles), phlebitis.

Similarities